Author:
Haworth Kellie B.,Setty Bhuvana A.
Publisher
Springer International Publishing
Reference128 articles.
1. Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, Grimer RJ (1999) Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 79(7-8):1185–1189. doi:
10.1038/sj.bjc.6690190
2. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9(5), e1001216. doi:
10.1371/journal.pmed.1001216
3. Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Wozniak W, Laskowska-Klita T (2006) Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma. Pol Merkur Lekarski 21(124):330–334
4. Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W (2010a) Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma. Adv Med Sci 55(2):266–272. doi:
10.2478/v10039-010-0043-2
5. Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W (2010b) A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Pol Merkur Lekarski 29(169):19–26